HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Amele, S.; Sandri, A. K.; Rodger, A.; Vandekerckhove, L.; Benfield, T.; Milinkovic, A.; Duvivier, C.; Stellbrink, H. -J.; Sambatakou, H.; Chkhartishvili, N.; Caldeira, L.; Laguno, M.; Domingo, P.; Wandeler, G.; Gisinger, M.; Kuzovatova, E.; Dragovic, G.; Knysz, B.; Matulionyte, R.; Rockstroh, J. K.; Lundgren, J. D.; Mocroft, A.; Peters, L.; Harxhi, A.; Losso, M.; Kundro, M.; Schmied, B.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; Wit, S. D.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Katzenstein, T.; Pedersen, C.; Johansen, I. S.; Ostergaard, L.; Wiese, L.; Moller, N. F.; Nielsen, L. N.; Zilmer, K.; Smidt, J.; Aho, I.; Viard, J. -P.; Girard, P. -M.; Pradier, C.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Behrens, G.; Degen, O.; Stellbrink, H. J.; Stefan, C.; Bogner, J.; Fatkenheuer, G.; Chkhartishvili, N.; Sambatakou, H.; Adamis, G.; Paissios, N.; Szlavik, J.; Gottfredsson, M.; Devitt, E.; Tau, L.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; D'Arminio Monforte, A.; Esposito, R.; Mazeu, I.; Mussini, C.; Mazzotta, F.; Gabbuti, A.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Sacco, L.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Dragas, S.; Stevanovic, M.; Reiss, P.; Trajanovska, J.; Reikvam, D. H.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Bakowska, E.; Flisiak, R.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Jablonowska, E.; Kamerys, J.; Wojcik, K.; Mozer-Lisewska, I.; Rozplochowski, B.; Zagalo, A.; Mansinho, K.; Maltez, F.; Radoi, R.; Oprea, C.; Davila, C.; Yakovlev, A.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Blokhina, I. N.; Novogrod, N.; Borodulina, E.; Vdoushkina, E.; Ranin, J.; Tomazic, J.; Miro, J. M.; Miro, J. M.; Martinez, E.; Garcia, F.; Blanco, J. L.; Martinez-Rebollar, M.; Mallolas, J.; Callau, P.; Rojas, J.; Inciarta, A.; Moreno, S.; del Campo, S.; Clotet, B.; Jou, A.; Paredes, R.; Puig, J.; Llibre, J. M.; Santos, J. R.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M. A.; Laporte, J. M.; Falconer, K.; Thalme, A.; Sonnerborg, A.; Brannstrom, J.; Flamholc, L.; Scherrer, A.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Schmid, P.; Kuznetsova, A.; Mikhalik, J.; Sluzhynska, M.; Milinkovic, A.; Johnson, A. M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M. A.; Mocroft, A.; Orkin, C.; Winston, A.; Clarke, A.; Leen, C.; Karpov, I.; Losso, M.; Lundgren, J.; Rockstroh, J.; Aho, I.; Rasmussen, L. D.; Svedhem, V.; Wandeler, G.; Pradier, C.; Chkhartishvili, N.; Matulionyte, R.; Oprea, C.; Kowalska, J. D.; Begovac, J.; Miro, J. M.; Guaraldi, G.; Paredes, R.; Wandeler, G.; Paredes, R.; Peters, L.; Kirk, O.; Peters, L.; Bojesen, A.; Raben, D.; Hansen, E. V.; Kristensen, D.; Larsen, J. F.; Fischer, A. H.; Mocroft, A.; Phillips, A.; Cozzi-Lepri, A.; Amele, S.; Pelchen-Matthews, A.; Roen, A.; Tusch, E.; Bannister, W.; Reekie, J.

doi:10.1111/hiv.13212

Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe / Amele, S.; Sandri, A. K.; Rodger, A.; Vandekerckhove, L.; Benfield, T.; Milinkovic, A.; Duvivier, C.; Stellbrink, H. -J.; Sambatakou, H.; Chkhartishvili, N.; Caldeira, L.; Laguno, M.; Domingo, P.; Wandeler, G.; Gisinger, M.; Kuzovatova, E.; Dragovic, G.; Knysz, B.; Matulionyte, R.; Rockstroh, J. K.; Lundgren, J. D.; Mocroft, A.; Peters, L.; Harxhi, A.; Losso, M.; Kundro, M.; Schmied, B.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; Wit, S. D.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Katzenstein, T.; Pedersen, C.; Johansen, I. S.; Ostergaard, L.; Wiese, L.; Moller, N. F.; Nielsen, L. N.; Zilmer, K.; Smidt, J.; Aho, I.; Viard, J. -P.; Girard, P. -M.; Pradier, C.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Behrens, G.; Degen, O.; Stellbrink, H. J.; Stefan, C.; Bogner, J.; Fatkenheuer, G.; Chkhartishvili, N.; Sambatakou, H.; Adamis, G.; Paissios, N.; Szlavik, J.; Gottfredsson, M.; Devitt, E.; Tau, L.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; D'Arminio Monforte, A.; Esposito, R.; Mazeu, I.; Mussini, C.; Mazzotta, F.; Gabbuti, A.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Sacco, L.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Dragas, S.; Stevanovic, M.; Reiss, P.; Trajanovska, J.; Reikvam, D. H.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Bakowska, E.; Flisiak, R.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Jablonowska, E.; Kamerys, J.; Wojcik, K.; Mozer-Lisewska, I.; Rozplochowski, B.; Zagalo, A.; Mansinho, K.; Maltez, F.; Radoi, R.; Oprea, C.; Davila, C.; Yakovlev, A.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Blokhina, I. N.; Novogrod, N.; Borodulina, E.; Vdoushkina, E.; Ranin, J.; Tomazic, J.; Miro, J. M.; Miro, J. M.; Martinez, E.; Garcia, F.; Blanco, J. L.; Martinez-Rebollar, M.; Mallolas, J.; Callau, P.; Rojas, J.; Inciarta, A.; Moreno, S.; del Campo, S.; Clotet, B.; Jou, A.; Paredes, R.; Puig, J.; Llibre, J. M.; Santos, J. R.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M. A.; Laporte, J. M.; Falconer, K.; Thalme, A.; Sonnerborg, A.; Brannstrom, J.; Flamholc, L.; Scherrer, A.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Schmid, P.; Kuznetsova, A.; Mikhalik, J.; Sluzhynska, M.; Milinkovic, A.; Johnson, A. M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M. A.; Mocroft, A.; Orkin, C.; Winston, A.; Clarke, A.; Leen, C.; Karpov, I.; Losso, M.; Lundgren, J.; Rockstroh, J.; Aho, I.; Rasmussen, L. D.; Svedhem, V.; Wandeler, G.; Pradier, C.; Chkhartishvili, N.; Matulionyte, R.; Oprea, C.; Kowalska, J. D.; Begovac, J.; Miro, J. M.; Guaraldi, G.; Paredes, R.; Wandeler, G.; Paredes, R.; Peters, L.; Kirk, O.; Peters, L.; Bojesen, A.; Raben, D.; Hansen, E. V.; Kristensen, D.; Larsen, J. F.; Fischer, A. H.; Mocroft, A.; Phillips, A.; Cozzi-Lepri, A.; Amele, S.; Pelchen-Matthews, A.; Roen, A.; Tusch, E.; Bannister, W.; Reekie, J.. - In: HIV MEDICINE. - ISSN 1464-2662. - 23:6(2022), pp. 684-692. [10.1111/hiv.13212]

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Amele S.;Sandri A. K.;Rodger A.;Vandekerckhove L.;Benfield T.;Milinkovic A.;Duvivier C.;Stellbrink H. -J.;Sambatakou H.;Chkhartishvili N.;Caldeira L.;Laguno M.;Domingo P.;Wandeler G.;Gisinger M.;Kuzovatova E.;Dragovic G.;Knysz B.;Matulionyte R.;Rockstroh J. K.;Lundgren J. D.;Mocroft A.;Peters L.;Harxhi A.;Losso M.;Kundro M.;Schmied B.;Zangerle R.;Karpov I.;Vassilenko A.;Mitsura V. M.;Paduto D.;Clumeck N.;Wit S. D.;Delforge M.;Florence E.;Vandekerckhove L.;Hadziosmanovic V.;Begovac J.;Machala L.;Jilich D.;Sedlacek D.;Kronborg G.;Benfield T.;Gerstoft J.;Katzenstein T.;Pedersen C.;Johansen I. S.;Ostergaard L.;Wiese L.;Moller N. F.;Nielsen L. N.;Zilmer K.;Smidt J.;Aho I.;Viard J. -P.;Girard P. -M.;Pradier C.;Fontas E.;Duvivier C.;Rockstroh J.;Behrens G.;Degen O.;Stellbrink H. J.;Stefan C.;Bogner J.;Fatkenheuer G.;Chkhartishvili N.;Sambatakou H.;Adamis G.;Paissios N.;Szlavik J.;Gottfredsson M.;Devitt E.;Tau L.;Turner D.;Burke M.;Shahar E.;Hassoun G.;Elinav H.;Haouzi M.;Elbirt D.;D'Arminio Monforte A.;Esposito R.;Mazeu I.;Mussini C.;Mazzotta F.;Gabbuti A.;Lazzarin A.;Castagna A.;Gianotti N.;Galli M.;Ridolfo A.;Sacco L.;Uzdaviniene V.;Matulionyte R.;Staub T.;Hemmer R.;Dragas S.;Stevanovic M.;Reiss P.;Trajanovska J.;Reikvam D. H.;Maeland A.;Bruun J.;Knysz B.;Gasiorowski J.;Inglot M.;Bakowska E.;Flisiak R.;Grzeszczuk A.;Parczewski M.;Maciejewska K.;Aksak-Was B.;Beniowski M.;Mularska E.;Jablonowska E.;Kamerys J.;Wojcik K.;Mozer-Lisewska I.;Rozplochowski B.;Zagalo A.;Mansinho K.;Maltez F.;Radoi R.;Oprea C.;Davila C.;Yakovlev A.;Trofimora T.;Khromova I.;Kuzovatova E.;Blokhina I. N.;Novogrod N.;Borodulina E.;Vdoushkina E.;Ranin J.;Tomazic J.;Miro J. M.;Miro J. M.;Martinez E.;Garcia F.;Blanco J. L.;Martinez-Rebollar M.;Mallolas J.;Callau P.;Rojas J.;Inciarta A.;Moreno S.;del Campo S.;Clotet B.;Jou A.;Paredes R.;Puig J.;Llibre J. M.;Santos J. R.;Domingo P.;Gutierrez M.;Mateo G.;Sambeat M. A.;Laporte J. M.;Falconer K.;Thalme A.;Sonnerborg A.;Brannstrom J.;Flamholc L.;Scherrer A.;Weber R.;Cavassini M.;Calmy A.;Furrer H.;Battegay M.;Schmid P.;Kuznetsova A.;Mikhalik J.;Sluzhynska M.;Milinkovic A.;Johnson A. M.;Simons E.;Edwards S.;Phillips A.;Johnson M. A.;Mocroft A.;Orkin C.;Winston A.;Clarke A.;Leen C.;Karpov I.;Losso M.;Lundgren J.;Rockstroh J.;Aho I.;Rasmussen L. D.;Svedhem V.;Wandeler G.;Pradier C.;Chkhartishvili N.;Matulionyte R.;Oprea C.;Kowalska J. D.;Begovac J.;Miro J. M.;Guaraldi G.;Paredes R.;Wandeler G.;Paredes R.;Peters L.;Kirk O.;Peters L.;Bojesen A.;Raben D.;Hansen E. V.;Kristensen D.;Larsen J. F.;Fischer A. H.;Mocroft A.;Phillips A.;Cozzi-Lepri A.;Amele S.;Pelchen-Matthews A.;Roen A.;Tusch E.;Bannister W.;Reekie J.

2022

Abstract

Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.

Scheda breve

Scheda completa

Scheda completa (DC)

	Anno di pubblicazione
	
				2022
			
	Data di prima pubblicazione
	
				9-dic-2021
			
	Rivista
	
				HIV MEDICINE
			
	N° del Volume
	
				23
			
	Fascicolo
	
				6
			
	Pagina iniziale
	
				684
			
	Pagina finale
	
				692
			
	Codice DOI
	
				https://dx.doi.org/10.1111/hiv.13212
			
	Codice WoS
	
				WOS:000728266000001
			
	Codice Scopus
	
				2-s2.0-85120978428
			
	Codice PubMed
	
				34882940
			
	Citazione
	
				HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe / Amele, S.; Sandri, A. K.; Rodger, A.; Vandekerckhove, L.; Benfield, T.; Milinkovic, A.; Duvivier, C.; Stellbrink, H. -J.; Sambatakou, H.; Chkhartishvili, N.; Caldeira, L.; Laguno, M.; Domingo, P.; Wandeler, G.; Gisinger, M.; Kuzovatova, E.; Dragovic, G.; Knysz, B.; Matulionyte, R.; Rockstroh, J. K.; Lundgren, J. D.; Mocroft, A.; Peters, L.; Harxhi, A.; Losso, M.; Kundro, M.; Schmied, B.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; Wit, S. D.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Katzenstein, T.; Pedersen, C.; Johansen, I. S.; Ostergaard, L.; Wiese, L.; Moller, N. F.; Nielsen, L. N.; Zilmer, K.; Smidt, J.; Aho, I.; Viard, J. -P.; Girard, P. -M.; Pradier, C.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Behrens, G.; Degen, O.; Stellbrink, H. J.; Stefan, C.; Bogner, J.; Fatkenheuer, G.; Chkhartishvili, N.; Sambatakou, H.; Adamis, G.; Paissios, N.; Szlavik, J.; Gottfredsson, M.; Devitt, E.; Tau, L.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; D'Arminio Monforte, A.; Esposito, R.; Mazeu, I.; Mussini, C.; Mazzotta, F.; Gabbuti, A.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Sacco, L.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Dragas, S.; Stevanovic, M.; Reiss, P.; Trajanovska, J.; Reikvam, D. H.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Bakowska, E.; Flisiak, R.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Jablonowska, E.; Kamerys, J.; Wojcik, K.; Mozer-Lisewska, I.; Rozplochowski, B.; Zagalo, A.; Mansinho, K.; Maltez, F.; Radoi, R.; Oprea, C.; Davila, C.; Yakovlev, A.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Blokhina, I. N.; Novogrod, N.; Borodulina, E.; Vdoushkina, E.; Ranin, J.; Tomazic, J.; Miro, J. M.; Miro, J. M.; Martinez, E.; Garcia, F.; Blanco, J. L.; Martinez-Rebollar, M.; Mallolas, J.; Callau, P.; Rojas, J.; Inciarta, A.; Moreno, S.; del Campo, S.; Clotet, B.; Jou, A.; Paredes, R.; Puig, J.; Llibre, J. M.; Santos, J. R.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M. A.; Laporte, J. M.; Falconer, K.; Thalme, A.; Sonnerborg, A.; Brannstrom, J.; Flamholc, L.; Scherrer, A.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Schmid, P.; Kuznetsova, A.; Mikhalik, J.; Sluzhynska, M.; Milinkovic, A.; Johnson, A. M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M. A.; Mocroft, A.; Orkin, C.; Winston, A.; Clarke, A.; Leen, C.; Karpov, I.; Losso, M.; Lundgren, J.; Rockstroh, J.; Aho, I.; Rasmussen, L. D.; Svedhem, V.; Wandeler, G.; Pradier, C.; Chkhartishvili, N.; Matulionyte, R.; Oprea, C.; Kowalska, J. D.; Begovac, J.; Miro, J. M.; Guaraldi, G.; Paredes, R.; Wandeler, G.; Paredes, R.; Peters, L.; Kirk, O.; Peters, L.; Bojesen, A.; Raben, D.; Hansen, E. V.; Kristensen, D.; Larsen, J. F.; Fischer, A. H.; Mocroft, A.; Phillips, A.; Cozzi-Lepri, A.; Amele, S.; Pelchen-Matthews, A.; Roen, A.; Tusch, E.; Bannister, W.; Reekie, J.. - In: HIV MEDICINE. - ISSN 1464-2662. - 23:6(2022), pp. 684-692. [10.1111/hiv.13212]
			
	Tutti gli autori
	
						Amele, S.; Sandri, A. K.; Rodger, A.; Vandekerckhove, L.; Benfield, T.; Milinkovic, A.; Duvivier, C.; Stellbrink, H. -J.; Sambatakou, H.; Chkhartishvi...espandi
						
	Tipologia
	
				Articolo su rivista

File in questo prodotto:

File	Dimensione	Formato
HIV Medicine - 2021 - Amele - HCV reinfection after HCV therapy among HIV HCV‐coinfected individuals in Europe.pdf Accesso riservato Tipologia: Versione pubblicata dall'editore Dimensione 190.05 kB Formato Adobe PDF Visualizza/Apri Richiedi una copia	190.05 kB	Adobe PDF	Visualizza/Apri Richiedi una copia
Cozzi-Lepri_HCV reinfection after HCV therapy among HIV HCV-coinfected individuals in Europe_AAM.pdf Open Access dal 01/01/2024 Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione Dimensione 215.04 kB Formato Adobe PDF Visualizza/Apri	215.04 kB	Adobe PDF	Visualizza/Apri

Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris